Coating potential of a new modified starch coating for immediate release oral tablets

Rumman, Tareq A.; Al-Ani, Israa; Hassan, Samira F.

doi:10.1007/s11998-014-9618-3

Cited by 3 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Volume was completed to 3 L and additional 15 min of stirring were added to ensure homogenization. The coating dispersion was freshly prepared before each coating run (17). Due to small number of tablets prepared, the coating pan was loaded with placebo tablets (made of compressed avicel) to make tablets rolling over and the optimization of coating parameters easier (17) .…”

Section: Coating Processmentioning

confidence: 99%

“…The coating dispersion was freshly prepared before each coating run (17). Due to small number of tablets prepared, the coating pan was loaded with placebo tablets (made of compressed avicel) to make tablets rolling over and the optimization of coating parameters easier (17) . The tablets prepared for the animal study were smaller in size (50 mg wt.)…”

Section: Coating Processmentioning

confidence: 99%

“…Different types of Opadry are available depending on the type of polymer if it produces immediate release, controlled release or enteric coating. (17) Xanthan gum is an extracellular polysaccharide secreted by the microorganism Xanthomonas campestris. Commercially it is manufactured by a fermentation process.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients

Аlmajidi

Khalaf²,

Shalan³

et al. 2022

IJPS

View full text Add to dashboard Cite

Oro slippery tablets (OSTs) is a technique used to improve swallowing of tablets for patients with dysphagia. The aim of this study was to formulate irbesartan and hydrochlorothiazide as Oroslippery tablets (OST) containing 150 mg irbesartan and 25 mg hydrochlorothiazide for dysphagia patients. A simple and rapid method of analysis was developed and validated according to the ICH guideline using HPLC with UV detector. Tablets were prepared by direct compression and then coated with the slippery coat of three different concentrations of the slippering substance “xanthan gum’ (2%, 3% and 4%) in Opadry Colorcone® and evaluated according to USP. Slipperiness test was performed using Albino rabbits. Results showed that 2% xanthan gum gave the shortest swallowing time. Also, disintegration time was increased by the coat significantly with the increase of the gum’s concentration in the coat. The release kinetics study of the tested formulations (uncoated versus coated with 2% gum) gave the highest correlation for the "first-order release model" for both drugs in the absence and presence of the slippering agent which indicates that the coating did not interfere with the release kinetics of both drugs. In a conclusion, 2% xanthan gum as slippering agent the optimum concentration used to promote easy ingestion of this tablet.

show abstract

Section: Coating Processmentioning

confidence: 99%

Section: Coating Processmentioning

confidence: 99%

See 1 more Smart Citation

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients

Аlmajidi

Khalaf²,

Shalan³

et al. 2022

IJPS

View full text Add to dashboard Cite

show abstract

“…Modified starches are used as excipients in medicinal products and, in particular, in medicinal products that come in various types of tablet forms, such as sustained/extended release tablets, film-coated tablets, orally disintegrating tablets and chewable tablets (mostly analgesics). Their function in pharmaceuticals is described as tablet disintegrant for immediate drug release, as controlled/sustained release polymer for drugs and hormones (Singh and Nath, 2010;Ochubiojo and Rodrigues, 2012;Rumman et al, 2015) and for encapsulation purposes. They are also used in medicinal products that come in powder form (such as antiflu preparations to be taken orally or antifungal powders for local external use) and as plasma volume expander for trauma, heavy blood loss and cancer.…”

Section: Pharmaceutical Usesmentioning

confidence: 99%

“…The in vitro digestibility of a distarch phosphate using trimetaphosphate, by salivary, pancreatic and intestinal amylase was measured by the production rate of reducing sugar (Rosner, 1960;cited in JECFA, 1974b). No deleterious effect was shown on enzymic depolymerisation.…”

Section: Distarch Phosphate (E 1412)mentioning

confidence: 99%

Re‐evaluation of oxidised starch (E 1404), monostarch phosphate (E 1410), distarch phosphate (E 1412), phosphated distarch phosphate (E 1413), acetylated distarch phosphate (E 1414), acetylated starch (E 1420), acetylated distarch adipate (E 1422), hydroxypropyl starch (E 1440), hydroxypropyl distarch phosphate (E 1442), starch sodium octenyl succinate (E 1450), acetylated oxidised starch (E 1451) and starch aluminium octenyl succinate (E 1452) as food additives

Mortensen¹,

Aguilar²,

Crebelli³

et al. 2017

EFS2

View full text Add to dashboard Cite

Following a request from the European Commission, the EFSA Panel on Food Additives and Nutrient sources added to Food (ANS) was asked to deliver a scientific opinion on the re-evaluation of 12 modified starches (E 1404, E 1410, E 1412, E 1413, E 1414, E 1420, E 1422, E 1440, E 1442, E 1450, E 1451 and E 1452) authorised as food additives in the EU in accordance with Regulation (EC) No 1333/2008 and previously evaluated by JECFA and the SCF. Both committees allocated an acceptable daily intake (ADI) 'not specified'. In humans, modified starches are not absorbed intact but significantly hydrolysed by intestinal enzymes and then fermented by the intestinal microbiota. Using the read-across approach, the Panel considered that adequate data on short-and long-term toxicity and carcinogenicity, and reproductive toxicity are available. Based on in silico analyses, modified starches are considered not to be of genotoxic concern. No treatment-related effects relevant for human risk assessment were observed in rats fed very high levels of modified starches (up to 31,000 mg/kg body weight (bw) per day). Modified starches (e.g. E 1450) were well tolerated in humans up to a single dose of 25,000 mg/person. Following the conceptual framework for the risk assessment of certain food additives, the Panel concluded that there is no safety concern for the use of modified starches as food additives at the reported uses and use levels for the general population and that there is no need for a numerical ADI. The combined exposure to E 1404-E 1451 at the 95th percentile of the refined (brand-loyal) exposure assessment scenario for the general population was up to 3,053 mg/kg bw per day. Exposure to E 1452 for food supplement consumers only at the 95th percentile was up to 22.1 mg/kg bw per day.

show abstract

Oral Delivery of Anti-Diabetic Drugs Using Bio-Based Polymeric Nanoparticles: A Review of Recent Advances

Maji

Sharma

2023

Preprint

View full text Add to dashboard Cite

Oral delivery of anti-diabetic drugs, especially insulin, possesses enormous potential in the future of diabetes treatment. Various platforms and methods have been brought to light in the last decade as nanotechnology underwent a tremendous growth spurt. These systems focus on enhancing absorption, permeation, and bioavailability of active agents while overcoming physicochemical and biological barriers in the gastrointestinal tract. Formulations with bio-polymeric nanoparticles as delivery vehicles have received extensive attention owing to positive traits like biocompatibility, biodegradability, low immunogenicity, and low cost. In recent works, the focus has been given to systems with incorporated nano-sensors, site-specific targeting, and sustained, controlled, and stimuli-responsive release. In this article, we discuss the current state and future prospects of biopolymeric nanoparticulate systems for the oral delivery of anti-diabetic drugs.

show abstract

Coating potential of a new modified starch coating for immediate release oral tablets

Cited by 3 publications

References 11 publications

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients

Oral Delivery of Anti-Diabetic Drugs Using Bio-Based Polymeric Nanoparticles: A Review of Recent Advances

Contact Info

Product

Resources

About